One-shot MRI to map brain tumors in a single scan
Official title: One-shot morphologic, hemodynamic and metabolic MR imaging of brain tumors
Funded at Arizona State University-Tempe Campus · NIH-11418946 · Data updated 2026-11-12
A new MRI approach uses one contrast agent to map shape, blood flow, and metabolism of brain tumors in a single session to guide care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Arizona State University-Tempe Campus NIH-funded |
| Lab location | 1 site (Scottsdale, United States) |
| Project start | July 5, 2021 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $589,526 |
| NIH project number | 5R01CA264934-05 |
| Project ID | NIH-11418946 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with brain tumors who require imaging for biopsy planning, treatment planning, or monitoring.
✕Less likely to help
Patients who cannot receive contrast agents or have conditions that limit MRI use may not benefit.
What this research studies
This project aims to validate a practical MRI method that combines multiple imaging features into one exam for brain tumor patients. Patients would receive a single contrast dose, and doctors would obtain information about tumor structure, blood flow, and metabolism from one imaging session. The research compares this approach to current multi-scan practices to see if it can reliably reveal tumor hypoxia and other pathologies that influence treatment. If successful, it could streamline imaging workflows, reduce patient burden, and support better treatment planning.
Why it matters
Potential benefit: If successful, patients could experience faster, more comprehensive imaging with fewer scans and contrast injections, aiding personalized treatment decisions.
How similar studies have gone: Previous work shows potential in multiparametric MRI, but this one-shot approach focuses on clinical feasibility and comprehensive tumor mapping.
Where this research is happening
-
Arizona State University-Tempe Campus
Scottsdale, United States Active
Researchers
- Principal investigator: Kodibagkar, Vikram D. — Arizona State University-Tempe Campus
- Study coordinator: Kodibagkar, Vikram D.
Related research
Other NIH-funded projects on the same topics.
-
ONC206 for children with brain tumors: a first-in-children trial
A first-in-children trial will test the safety and early signs of effectiveness of ONC206, taken by mouth, in kids with malignant brain tumors like diffuse midline gliomas.
-
ONC206 for children with malignant brain tumors
A first-in-children trial tests the safety and early effectiveness of a pill that can cross the brain barrier to treat pediatric brain tumors.
-
ONC206 for children with dangerous brain tumors
A first-in-children study tests the safety and early effectiveness of an oral drug, ONC206, for kids with high-risk brain tumors that have spread or recurred.
-
Oral bacteria and brain metastasis: how the mouth may influence brain tumors
A study exploring how oral microbes may affect brain metastases and patient outcomes, with potential to guide new microbiome-based approaches.
-
Bioengineered brain barrier chip to improve drug screening for brain tumors
A small, patient-friendly brain barrier chip is being developed to test drugs for glioblastoma more accurately before they reach clinical trials.
-
Understanding how epigenetic changes drive pediatric brain tumor recurrence and how reversing them could help
A pediatric brain cancer research project is exploring how an epigenetic change (H3K27M) and tumor environment contribute to tumor coming back, using a reversible mouse model to study potential ways to prevent recurrence.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.